ABSTRACT
As the COVID-19 pandemic continues to surge in the United States, it has become clear that infection risk is higher in certain populations, particularly socially and economically marginalized groups. Social risk factors, together with other demographic and community characteristics, may reveal local variations and inequities in COVID risk that could be useful for targeting testing and interventions. Yet to date, rates of infection and estimations of COVID risk are typically reported at the county and state level. In this study we develop a small area vulnerability index based on publicly-available sociodemographic data and 668,428 COVID diagnoses reported in 4,803 ZIP codes in the United States (15% of all ZIP codes). The outcome was COVID-19 diagnosis rates per 100,000 people by ZIP code. Explanatory variables included sociodemographic characteristics obtained from the 2018 American Community Survey 5-year estimates. Bayesian multivariable techniques were used to capture complexities of spatial data and spatial autocorrelation and identify individual risk factors and derive their respective weights in the index. COVID-19 diagnosis rates varied from zero to 29,508 per 100,000 people. The final vulnerability index showed that higher population density, higher percentage of noninsured, nonwhite race and Hispanic ethnicity were positively associated with COVID-19 diagnosis rates. Our findings indicate disproportionate risk of COVID-19 infection among some populations and validate and expand understanding of these inequities, integrating several risk factors into a summary index reflecting composite vulnerability to infection. This index can provide local public health and other agencies with evidence-based metrics of COVID risk at a geographical scale that has not been previously available to most US communities.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not a clinical trial
Funding Statement
no external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study use de-identified publicly available data and did not warrant a review by an Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
